Known Medicine Analysis: $7M Raised
What is Known Medicine?
Known Medicine is building a machine learning-based system to predict how individual cancers respond to specific treatments. The company combines living patient cells, 3D cell culture experiments, and omics data to identify predictive biomarkers and likely responders. It says it is creating a large 3D cell culture dataset to improve treatment matching for future patients.
Location
675 Arapeen Dr. Ste 103A-1, Salt Lake City, UT 84108, United States
Employees
1-10
Founded
2020
Revenue
$1.1M - <$5M
Product Features & Capabilities
- 3D cell culture dataset, machine learning-based sensitivity assay, micro-tumor platform, drug response prediction, personalized cancer treatment.
How much Known Medicine raised
Seed - $7.2 million
August 25, 2021Lead Investor: Caffeinated Capital, and others
HQ Full Address
675 Arapeen Dr. Ste 103A-1, Salt Lake City, UT 84108, United States
Market Focus
Known Medicine primarily focuses on the biotechnology and pharmaceutical industry, specifically in the area of cancer treatment and drug response prediction using machine learning and -omics data.
Investors
- Caffeinated Capital
- Khosla Ventures
- Y Combinator
- Chris Gibson (Angel Investor)
Competitors Overview
Known Medicine operates in the precision medicine sector, specifically focusing on drug response prediction using machine learning and -omics data. Its main competitors include:
-
Lantern Pharma: This company utilizes artificial intelligence and machine learning to enhance oncology drug discovery and development. Their proprietary RADR® platform integrates multi-omic data to predict drug responses, which is similar to Known Medicine's approach but may differ in the specific algorithms and data integration techniques used.
-
Predictive Oncology Inc.: Focused on AI-driven drug discovery, this company specializes in predicting cancer treatment responses. They leverage large datasets to inform treatment decisions, which positions them as a direct competitor in the oncology space.
-
NIH AI Tool: The National Institutes of Health has developed an AI tool that employs machine learning to predict cancer drug responses. While not a commercial competitor, it represents significant academic and research advancements in the field that could influence market dynamics.
-
Inside Precision Medicine: This company combines machine learning with transcriptomics to predict patient responses to cancer drugs. Their focus on single-cell precision may offer advantages in understanding tumor heterogeneity compared to broader approaches.
These competitors highlight the growing trend of integrating AI and machine learning in oncology, with each company bringing unique methodologies and technologies to the market.
See something that needs updating? Suggest edits to this profile.